A carregar...
Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
Alectinib is a key drug for treating anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of ALK-positive adenocarcinoma succes...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7983536/ https://ncbi.nlm.nih.gov/pubmed/33776703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513624 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|